Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Dose Response Trial of Pergolide for Cocaine Dependence - 1

This study has been completed.
Information provided by:
Medical University of South Carolina Identifier:
First received: September 20, 1999
Last updated: September 11, 2012
Last verified: May 1997

The purpose of this study is to evaluate the efficacy and safety of pergolide for treatment of cocaine dependence.

Condition Intervention Phase
Cocaine-Related Disorders
Drug: Pergolide
Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Dose Response Trial of Pergolide for Cocaine Dependence

Resource links provided by NLM:

Further study details as provided by Medical University of South Carolina:

Primary Outcome Measures:
  • Side effects
  • Drug use
  • Retention
  • Cocaine withdrawal
  • Compliance
  • Effectiveness of medication for global improvements

Estimated Enrollment: 0
Study Start Date: February 1996

Ages Eligible for Study:   21 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Please contact site for information.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00000248

United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425 742
Sponsors and Collaborators
Medical University of South Carolina
Principal Investigator: Robert Malcolm, M.D. Medical University of South Carolina
  More Information

No publications provided Identifier: NCT00000248     History of Changes
Other Study ID Numbers: NIDA-08355-1, R01DA008355, R01-08355-1
Study First Received: September 20, 1999
Last Updated: September 11, 2012
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Substance-Related Disorders
Dopamine Agents
Dopamine Agonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs processed this record on November 25, 2014